Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 698 of 5804
-
Freezing away heart flutters: new study tests Long-Term control of persistent AF
Disease control OngoingThe STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.
Sponsor: Medtronic Cardiac Ablation Solutions • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for tough lung cancer: experimental combos tested in 110 patients
Disease control OngoingThis study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC in need of second-line treatment. This study will ha…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New proton beam trial aims to spare healthy tissue in kids with kidney cancer
Disease control Recruiting nowParticipants are being asked to take part in this clinical trial, a type of research study, because the participants have a Wilms Tumor cancer. Primary Objectives To determine whether delivery of proton beam radiation to a conformal reduced target volume in the flank allows nor…
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail aims to boost remission in rare blood cancer
Disease control OngoingIn Waldenström macroglobulinemia (WM) chemotherapy induces only low CR/VGPR (Complete Remission/ Very Good Partial Response) rates and responses of short duration compared to other indolent lymphomas. Thus, innovative approaches are needed which combine excellent activity and tol…
Phase: PHASE2 • Sponsor: Christian Buske • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Immunotherapy cocktail shows promise in shrinking esophageal tumors before surgery
Disease control CompletedThe purpose of this study is to evaluate the pathological complete response (pCR) in participants receiving tislelizumab plus chemotherapy/chemoradiotherapy as neoadjuvant treatment.
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Brain zap tailored to each patient could tame tough OCD
Disease control Recruiting nowDeep brain stimulation (DBS) is an effective treatment for people suffering from severe obsessive-compulsive disorder (OCD) whose symptoms have failed to improve after years and multiple methods of intervention. An effective DBS target for OCD is the anterior limb of the internal…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug could save lives from shock after severe bleeding
Disease control Recruiting nowThis is a prospective, multi-centric, open-labeled, phase-IV clinical study to evaluate the safety and efficacy of centhaquine citrate (LYFAQUIN™), a first-in-class drug for treating hypovolemic shock, a life-threatening condition caused by severe blood or fluid loss. Centhaquine…
Phase: PHASE4 • Sponsor: Pharmazz, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill shows promise for rare tumors in Mid-Stage trial
Disease control Recruiting nowThis is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal s…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Triple-Drug attack shows promise against tough prostate cancer
Disease control Recruiting nowThis is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy cancer cells). This study will assess whether 225Ac-…
Phase: PHASE1, PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for kids with severe colitis: oral drug shows promise
Disease control OngoingThis study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of the US or EU,…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New 'See and Treat' approach targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThe aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Phase: PHASE1, PHASE2 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New GERD drug aims to heal esophagus damage when standard treatments fail
Disease control CompletedThis study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically unhealed (LA grades A or B) after 8 weeks history of st…
Phase: PHASE2 • Sponsor: Cinclus Pharma Holding AB • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for kids with tough cancers: drug combo trial launches
Disease control Recruiting nowThis study will test the safety of the study drug, repotrectinib, in combination with chemotherapy (irinotecan and temozolomide) in children and young adults who have advanced or metastatic solid tumors. We researchers will try to find the highest dose of the study drug that caus…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Monthly shot may boost opioid treatment success in hospitals
Disease control CompletedThis study is a multi-site open-label randomized comparative effectiveness trial of a 28-day formulation of extended-release buprenorphine (XR-BUP) versus treatment as usual (TAU) for hospitalized patients with a moderate or severe opioid use disorder (OUD) seen by an addiction c…
Phase: PHASE2, PHASE3 • Sponsor: Gavin Bart • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could a drug combo reverse liver scarring in NASH patients?
Disease control CompletedThe goal of this clinical study is to understand whether the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), cause fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants with cirrhosis due…
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Supercharged t cells take on childhood cancers
Disease control OngoingPatients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called AGAR T cells, a new experimental treatment. The body has different way…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug cocktail aims to shrink head and neck tumors
Disease control OngoingIn this study, patients with recurrent or metastatic head and neck squamous cell carcinoma will receive first line treatment with olaparib, pembrolizumab, and carboplatin. The primary hypothesis is that olaparib, pembrolizumab and carboplatin will result in an overall response ra…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Heart pump may protect patients during risky stent procedures
Disease control OngoingOver 100,000 coronary stent procedures, where small balloons are used to stretch open a narrowed blood vessel, are performed every year in the United Kingdom to treat people who have conditions such as angina or have suffered a heart attack. For most patients the risk of complic…
Phase: PHASE3 • Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Could a single infusion of COVID-Fighting antibodies keep High-Risk patients out of the hospital?
Disease control TerminatedThe primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo among adults with recently d…
Phase: PHASE3 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New device aims to seal brain aneurysms without open surgery
Disease control OngoingThe purpose of this trial is to gather data on the safety and effectiveness of the Contour /Contour 021 System in the treatment of wide-necked bifurcated saccular, intracranial aneurysms for submission to FDA in support of a premarket approval application for the device.
Phase: PHASE4 • Sponsor: Cerus Endovascular, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC